The stock of Genocea Biosciences Inc (NASDAQ:GNCA) is a huge mover today! About 296,395 shares traded hands. Genocea Biosciences Inc (NASDAQ:GNCA) has declined 8.70% since March 11, 2016 and is downtrending. It has underperformed by 14.15% the S&P500.
The move comes after 7 months negative chart setup for the $127.75M company. It was reported on Oct, 14 by Barchart.com. We have $3.58 PT which if reached, will make NASDAQ:GNCA worth $14.05M less.
Analysts await Genocea Biosciences Inc (NASDAQ:GNCA) to report earnings on November, 3. They expect $-0.42 EPS, down 13.51% or $0.05 from last year’s $-0.37 per share. After $-0.39 actual EPS reported by Genocea Biosciences Inc for the previous quarter, Wall Street now forecasts 7.69% negative EPS growth.
Genocea Biosciences Inc (NASDAQ:GNCA) Ratings Coverage
Out of 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genocea Biosciences has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of Genocea Biosciences Inc (NASDAQ:GNCA) earned “Outperform” rating by FBR Capital on Monday, October 19. The firm has “Overweight” rating given on Thursday, August 6 by Piper Jaffray. The firm has “Buy” rating by UBS given on Thursday, December 17. The rating was maintained by Needham on Tuesday, October 20 with “Buy”. Needham maintained it with “Buy” rating and $15 target price in Thursday, September 29 report. The stock of Genocea Biosciences Inc (NASDAQ:GNCA) has “Buy” rating given on Tuesday, August 11 by Needham. On Thursday, September 29 the stock rating was maintained by PiperJaffray with “Overweight”.
According to Zacks Investment Research, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts.”
More recent Genocea Biosciences Inc (NASDAQ:GNCA) news were published by: Fool.com which released: “Why It’s Been a Wild Few Days for Genocea Biosciences Inc.” on April 01, 2016. Also 247Wallst.com published the news titled: “Genocea Biosciences Posts Positive Herpes Trial Results” on September 29, 2016. Wsj.com‘s news article titled: “Genocea Biosciences Shares Dive as Vaccine Candidate Misses Goals” with publication date: October 19, 2015 was also an interesting one.
GNCA Company Profile
Genocea Biosciences, Inc., incorporated on August 16, 2006, is a biopharmaceutical company. The Firm discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. The Company’s ATLAS discovery platform is designed to overcome the challenges associated with developing vaccines that stimulate T cell immunity. The Company’s ATLAS is a throughput system for T cell vaccine and immunotherapy discovery. The Firm operates through business of developing and commercializing vaccines segment. The Firm has one product candidate in Phase II clinical development: GEN-003.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.